Therapeutic efficacy of cardiosphere-derived cells in a transgenic mouse model of non-ischaemic dilated cardiomyopathy

Mohammad A. Aminzadeh, Eleni Tseliou, Baiming Sun, Ke Cheng, Konstantinos Malliaras, Raj R. Makkar, and Eduardo Marbán*

Cedars-Sinai Heart Institute, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA

Received 30 July 2013; revised 22 January 2014; accepted 3 March 2014; online publish-ahead-of-print 27 May 2014

Aim
Cardiosphere-derived cells (CDCs) produce regenerative effects in the post-infarct setting. However, it is unclear whether CDCs are beneficial in non-ischaemic dilated cardiomyopathy (DCM). We tested the effects of CDC transplantation in mice with cardiac-specific Gαq overexpression, which predictably develop progressive cardiac dilation and failure, with accelerated mortality.

Methods and results
Wild-type mouse CDCs (10^5 cells) or vehicle only were injected intramyocardially in 6-, 8-, and 11-week-old Gαq mice. Cardiac function deteriorated in vehicle-treated mice over 3 months of follow-up, accompanied by oxidative stress, inflammation and adverse ventricular remodelling. In contrast, CDCs preserved cardiac function and volumes, improved survival, and promoted cardiomyogenesis while blunting Gαq-induced oxidative stress and inflammation in the heart. The mechanism of benefit is indirect, as long-term engraftment of transplanted cells is vanishingly low.

Conclusions
Cardiosphere-derived cells reverse fundamental abnormalities in cell signalling, prevent adverse remodelling, and improve survival in a mouse model of DCM. The ability to impact favourably on disease progression in non-ischaemic heart failure heralds new potential therapeutic applications of CDCs.

Keywords
Cardiomyopathy • Heart failure • Cell transplantation

Introduction
Cardiosphere-derived cells (CDCs) are regenerative and protective in the post-infarct setting, both in animal models1 – 5 and in patients.6 However, it is unclear whether CDCs exert any beneficial effects on non-ischaemic dilated cardiomyopathy (DCM). No models of DCM faithfully recapitulate the human condition in all its intricacies. Nevertheless, mice with cardiac-specific Gαq overexpression (Gαq mice) predictably develop progressive cardiac dilation and failure, and die prematurely in the absence of therapy.7,8 The pathophysiology of Gαq overexpression involves oxidative stress, inflammation, and apoptosis9 – 11 and thus mimics that of human heart failure in key respects.12 Cardiosphere-derived cells are known to exert anti-inflammatory, anti-fibrotic, and anti-apoptotic effects on injured myocardium.13 We, therefore, tested the concept that CDCs may be useful in a mouse model of DCM, by transplanting wild-type mouse CDCs into the hearts of Gαq mice. Cells were injected at various times during disease progression, so that we could detect either reversal of the phenotype, or prevention of further ventricular dysfunction.

Methods
Please see Supplementary material online, Methods. In brief, we studied male transgenic mice with cardiac-specific overexpression of Gαq [FVB/N-Tg (Myh6-Gnaq) 40Gwd/J] and male FVB/NJ mice (Jackson Laboratory, USA). Six-, 8-, and 11-week-old Gαq mice were randomized to CDC-treated or vehicle-treated groups and were followed for 3 months. FVB/NJ wild-type mice served as controls. Mouse CDCs were expanded from wild-type strain-matched
mouse hearts (FVB/NJ wild-type mouse heart). Intramyocardial injection, functional phenotyping, histological analysis, engraftment, and western blot protocols are described in Supplementary material online. Survival rate was assessed in Gq mice treated with cells or vehicle at 8 weeks of age, using the Kaplan–Meier approach. To accelerate heart failure progression and mortality, adriamycin (5 mg/kg) was administered intraperitoneally twice (at a 3-day interval) 3 weeks after cell or vehicle treatment and once again 6 weeks after cell/vehicle treatment in Gq mice and control FVB/NJ mice. Statistical analysis is described in detail in Supplementary material online. All the results are presented as means ± SEM. Analysis of variance followed by Bonferroni’s post hoc test, Mann–Whitney U test, and Kruskal–Wallis test followed by Dunn’s post test were applied in statistical analyses. The study followed pre-clinical reporting standards, as described previously.

Results

Changes in global cardiac function

Dilated cardiomyopathy is characterized by progressive ventricular dilatation and contractile dysfunction. Figure 1A shows representative echocardiographic images of hearts from wild-type, vehicle-treated Gq mice, and CDC-treated Gq mice. Cardiosphere-derived cell transplantation resulted in a sustained improvement of LVEF (Figure 1B–D) and LV end-diastolic and end-systolic volumes (Supplementary material online, Figure S1) in Gq mice, relative to placebo. This was true whether CDCs were injected at 6 (B), 8 (C), or 11 (D) weeks of age. Cardiosphere-derived cells did not restore lost function, but prevented the further progression of LV dysfunction.

Figure 1 Functional benefits after cardiosphere-derived cell transplantation. (A) representative long-axis echocardiographic images at end-diastole (upper row) and end-systole (lower row) in control (CTL; wild-type) and in vehicle (Gq+ vehicle) and CDC (Gq+CDC)-treated Gq mice that were injected at 11 weeks of age at 3 months after treatment. Pooled data for left ventricular function show that cardiosphere-derived cell transplantation resulted in a sustained improvement of ejection fraction for 3 months in Gq mice that received cardiosphere-derived cell at any of three different ages: 6 (B), 8 (C), and 11 (D) week old. Meanwhile, vehicle-treated Gq mice showed significant deterioration of cardiac function. Data are means ± SEM; n = 6–8 in each group. The Mann–Whitney U test was applied. *P < 0.05 vs. Gq+CDC; **P < 0.01 vs. Gq+CDC; ***P < 0.005 vs. Gq+CDC.
Figure 2 Prevention of oxidative/nitrosative stress with CDC treatment. Representative western blots and pooled data (A) and representative immunohistochemical images [B; CTL (wild-type), vehicle and cardiosphere-derived cell-treated Gqq mouse hearts stained for gp91phox, and 3-nitrotyrosine] from Gqq mice treated at 8 weeks of age. Membranes were stripped and GAPDH probed as a control for loading in each lane. Data are means ± SEM; n = 6–8 in each group. †P < 0.005 vs. Gqq+CDC and control (CTL; wild-type). Scale bars: 20 μm.
which was evident in the vehicle-treated animals. Robust preservation of cardiac function was sustained in CDC-treated animals for at least 3 months. Cardiosphere-derived cells also resulted in sustained preservation of LV anterior and posterior wall thickness for at least 3 months, in contrast to placebo-treated animals (Supplementary material online, Table S1 and Figure S2).

Cardiosphere-derived cell engraftment

Most of the benefit of CDC therapy is now recognized to be indirect, at least in ischaemic models. Consistent with previous observations, engraftment of CDCs at 1 week was \( \sim 10 \) and \( < 1\% \) at 3 weeks (Supplementary material online, Figure S3). By 6 weeks, no surviving CDCs could be detected. Thus, the long-term functional and structural benefits identified here must arise indirectly, rather than from direct differentiation of transplanted cells.

Oxidative stress and inflammation

Free radical injury is central to the pathophysiology of \( \text{Ga} \)q overexpression and DCM. We sought evidence of oxidative and nitrosative stress by measuring the protein levels of various relevant enzymes (Figure 2A). In vehicle-treated \( \text{Ga} \)q mice, we found markedly increased protein abundance of the NOX4, p47phox, p67phox, and gp91phox subunits (shown also immunohistochemically in Figure 2B, upper row) of the major reactive oxygen species (ROS)-producing enzyme, NAD(P)H oxidase, and augmented protein density of inducible nitric oxide synthase (iNOS). These changes were associated with accumulation of 3-nitrotyrosine (Figure 2A and B, lower row), which results from NO reaction with ROS.

The oxidative/nitrosative stress was accompanied by intense inflammation [as manifested by increased abundance of monocyte chemoattractant protein-1 (MCP-1), cyclooxygenase-2 (COX-2), and nuclear factor kappa B p65; Figure 3A], as well as accumulation of CD68\(^+\) macrophages and CD3\(^+\) T cells in hearts of vehicle-treated \( \text{Ga} \)q mice; Figure 3B and Supplementary material online, Figure S4A]. Thus, CDC treatment lowered 3-nitrotyrosine level, restored the protein abundance of NAD(P)H oxidase subunits, iNOS, MCP-1, and COX-2, prevented activation of NF-\( \kappa \)B p65, reduced infiltration of inflammatory cells, and increased the number and percentage (Supplementary material online, Figure S4) of reparative anti-inflammatory macrophages (M2 subtype;CD206\(^+\)) in the myocardium of 8-week-CDC-treated \( \text{Ga} \)q mice. Additionally, in vitro assessment of CDC-conditioned media and its effect on cultured cardiomyocytes stressed with hydrogen peroxide, a strong oxidant, confirmed the antioxidative/anti-apoptotic effects of CDCs. The expression of cleaved caspase 3 was markedly lower in the stressed cardiomyocytes incubated with CDC-conditioned media compared with the cardiomyocytes incubated with cardiac fibroblast-conditioned media or basal media (Supplementary material online, Figure S5), providing further evidence for suppression of oxidant-induced apoptosis. We conclude that CDCs attenuate oxidative/nitrosative stress and inflammation in \( \text{Ga} \)q mice.

Protein kinase C–protein kinase D–cAMP response element-binding protein (remodelling) pathway and apoptosis

The PKC (protein kinase C)–PKD (protein kinase D)–CREB (cAMP response element-binding protein) pathway contributes to cardiac

![Figure 3](https://academic.oup.com/eurheartj/article-abstract/36/12/751/428411) Suppression of inflammation with cardiosphere-derived cell treatment. Representative western blots and pooled data (A), and representative immunohistochemical images [B; CTL (wild-type), vehicle and cardiosphere-derived cell-treated \( \text{Ga} \)q mouse hearts stained for CD68, CD3, and CD20] from \( \text{Ga} \)q mice treated at 8 weeks of age. In CDC-treated \( \text{Ga} \)q mice, accumulation of CD68\(^+\) macrophages (B, upper row) and CD3\(^+\) T cells (B, middle row) was reduced. Membranes were stripped and GAPDH and histone H1 probed as a control for loading in each lane. Data are means \( \pm \) SEM; \( n = 6–8 \) in each group. \( 1^p < 0.005 \) vs. \( \text{Ga} \)q+ CDC and control (CTL; wild-type). Scale bars: 20 \( \mu \)m.
remodelling in Gαq mice. Figure 4A and C confirm that proteins involved in the PKC–PKD–CREB pathway are elevated in vehicle-treated Gαq mice, and that CDC treatment restored the levels of relevant proteins in the protein kinase C–protein kinase D–cAMP response element-binding protein remodelling pathway to those in non-diseased controls (C). Increased protein density of PKCβ was associated with elevated nuclear contents of its downstream active effectors, phosphorylated protein kinase D (Ser744/748) and phosphorylated cAMP response element-binding protein (Ser133) in the vehicle-treated Gαq mice. Increased abundance of active c-Jun N-terminal kinase, along with decreased active Akt protein density (Akt-pT308) and markedly higher numbers of cells positive for cleaved caspase 3 in vehicle-treated Gαq mice. Activation of the protein kinase C–protein kinase D–cAMP response element-binding protein remodelling pathway and increased apoptosis were ameliorated by cardiosphere-derived cell therapy. Arrows in (B) point to apoptotic cleaved caspase 3+ cells. Membranes were stripped and GAPDH probed as a control for loading in each lane. Phosphorylated protein kinase Cβ, protein kinase D, cAMP response element-binding protein, and Akt were normalized to total protein kinase Cβ, protein kinase D, cAMP response element-binding protein, and Akt, respectively. Quantification of JNK1 and JNK2 was performed using the same blots (D), taking advantage of the dual recognition of these two isoforms by the same antibody. Data are means ± SEM; n = 6–8 in each group. *P < 0.005 vs. Gαq+CDC and control (CTL; wild-type); scale bars: 10 μm (A), 20 μm (B).

**Cardiac fibrosis**

Cardiac fibrosis figures prominently in maladaptive responses to heart failure. Augmentation of collagen production and angiotensin II-mediated secretion of Krüppel-like factor 5 (KLF5) are among the compensatory mechanisms mediated by cardiac fibroblasts in heart failure, but sustained activation exacerbates fibrosis and, ultimately, leads to decompensated heart failure. In vehicle-treated Gαq mouse heart, collagen was increased [both histologically (Figure 5A–C) and at the protein level (Figure 5D)]; most of the collagen was co-localized with fibroblast-specific protein (FSP; Figure 5B and C). Cardiosphere-derived cell treatment markedly reduced cardiac collagen content, whether total or co-localized with FSP, and fibrosis (Figure 5A–D). In association with the increased abundance of collagen co-localized with FSP in vehicle-treated Gαq mouse heart, KLF5 and angiotensin II receptor type 1 (AT-R1)
protein levels (Figure 6A and B) were augmented, indicating concomitant up-regulation of AT-R1 and KLF5 (presumably in cardiac fibroblasts). Cardiosphere-derived cell treatment negated the up-regulation of KLF5 and AT-R1. In addition to restoration of KLF5 and AT-R1 protein expression, the activity of matrix metalloproteinase 9 (MMP9) was markedly increased in the CDC-treated hearts 1 day after treatment compared with the vehicle-treated group (Supplementary material online, Figure S6). Matrix metalloproteinases play a critical role in collagen degradation and in remodelling of extracellular matrix proteins in the heart.22

Figure 5 Cardiosphere-derived cell treatment markedly reduced cardiac collagen content and fibrosis. Representative Masson trichrome (A) and immunohistochemical images (B and C; CTL (wild-type), vehicle and cardiosphere-derived cell-treated Gqq mouse hearts stained for fibroblast-specific protein and collagen I) and representative western blots and pooled data (D) from Gqq mice treated at 8 weeks of age. Cardiosphere-derived cell treatment markedly reduced cardiac collagen content, whether total or co-localized with fibroblast-specific protein, and fibrosis (A–D). Membranes were stripped and GAPDH probed as a control for loading in each lane. Data are means ± SEM; *n = 6–8 in each group. *P < 0.005 vs. Gqq+ CDC and control (CTL; wild-type). **P < 0.05 vs. Gqq+ CDC and control (CTL; wild-type). Scale bars: 50 μm (A and B), 10 μm (C).
contrast, 1 week after CDC treatment, MMP9 activity decreased relative to vehicle-treated or wild-type mice. This dynamic pattern may reflect dual effects of CDCs on MMP9 activity, with the early increase contributing to collagen degradation, and the later reduction promoting survival and differentiation of cardiac stem cells as previously shown.23

Cardiomyogenesis and cardiac lineage differentiation
Cardiomyocyte cycling and proliferation are infrequent in the normal adult mouse heart, as illustrated here by the low numbers of Ki67+ and aurora B+ cardiomyocytes (Figure 7A and B and CTL bars in pooled data). The vehicle-treated Gαq myocardium exhibits a several-fold increase in the numbers of Ki67+ and aurora B+ cardiomyocytes (Figure 7A and B and middle bars in pooled data), presumably as a compensatory mechanism in response to the enhanced apoptosis (Figure 4B and D). Cardiosphere-derived cells increase endogenous cardiomyogenesis in ischaemic models.1–6 Likewise, CDC treatment promoted cardiomyogenesis in the Gαq model of DCM, as evidenced by a marked increase in Ki67+ and aurora B+ cardiomyocytes [Figure 7A and B and (Gq+CDC) bars in pooled data]. Previous work from our laboratory124 implicates paracrine signalling by CDCs in the mechanism of these effects, consistent with the findings here of evanescent transplanted cell survival (Supplementary material online, Figure S3). In addition to enhanced cardiomyogenesis, CDC treatment markedly increased cardiac lineage differentiation in the c-kit+ cells [Figure 7C and (Gq+CDC) bar in the pooled data]. The number of c-kit+ cells positive for Nkx2.5, an early cardiac transcription factor, was markedly higher in the CDC-treated hearts than in the other groups.

Survival analysis after adriamycin stress
Mortality is known to be enhanced in Gαq mice: the median survival is ≈1.5 years, whereas 78% of control mice survive >2 years.8 We accelerated heart failure progression even further by treating the mice with adriamycin. After ≈4 months, all vehicle-treated Gαq mice had died, whereas 60% of CDC-treated Gαq (or control) mice remained alive (Figure 8A). Survival was significantly attenuated in vehicle-treated Gαq mice relative to either CDC-treated Gαq mice or wild-type controls; the latter two groups, however, were statistically indistinguishable.

Nrf2-Keap1 antioxidant defence pathway
In physiological settings, cells respond to oxidative stress by activating the Nrf2-Keap1 antioxidant defence pathway.25 In vehicle-treated Gαq mice, despite severe oxidative/nitrosative stress (Figure 2), Nrf2 activity was impaired as evidenced by decreased nuclear content of Nrf2, increased cytoplasmic Keap1 protein density and, diminished expression of Nrf2 target gene products, catalase, and copper-zinc superoxide dismutase (Cu-Zn SOD). In contrast, CDC treatment restored the protein abundance of nuclear Nrf2.
cytoplasmic Keap1, catalase, and Cu-Zn SOD to control levels (Figure 8B).

**Discussion**

Figure 8C depicts schematically the various disease processes at play in the Gαq mouse, and how CDCs impact each of these. Intramyocardial administration of CDCs in a mouse model of DCM preserves cardiac function; improves survival; blunts oxidative stress, inflammation and remodelling; and enhances cardiomyogenesis. This is accompanied by lower levels of ROS- and NO-generating enzymes, mitigation of inflammatory and remodelling pathways, deactivation of pro-apoptotic and activation of pro-survival mediators, marked reduction in fibrosis and significant augmentation of cycling and proliferating cardiomyocytes in the CDC-treated Gαq mouse heart.

**Changes in cell signalling**

Administration of CDCs reversed the Gαq-induced up-regulation of ROS- and NO-generating enzymes, prevented activation of inflammatory pathways, markedly diminished infiltration of inflammatory cells and significantly enhanced accumulation of reparative anti-inflammatory macrophages into cardiac tissue in Gαq mice. Such effects are consistent with the immunomodulatory properties recently described for CDCs.26

In physiological settings, cells respond to oxidative stress by activating the Nrf2-Keap1 pathway. Upon oxidative modification of the inhibitory subunit Keap1 or phosphorylation of Nrf2, Nrf2 dissociates from Keap1, translocates to the nucleus and up-regulates genes encoding many antioxidant and phase II detoxifying enzymes.25 Despite severe oxidative/nitrosative stress, Nrf2 activity was impaired in Gαq mouse heart, a deficit reversed by CDCs (Figure 8B). It should be noted that, in CDC-treated Gαq mouse heart, protein abundance of phosphorylated/activated Akt was not only higher than that found in vehicle-treated Gαq mice, but also, even higher than the p-Akt content in wild-type mouse heart (Figure 4D). Given that Akt is among the protein kinases which phosphorylate Nrf2,27 CDC-mediated reversal of impaired Nrf2 may be mediated, at least partly, via augmentation of active Akt.

**Figure 7** Cardiosphere-derived cell treatment increased cardiomyocyte cycling and proliferation and augmented number of c-kit positive cells differentiating into cardiac lineage (c-kit⁺Nkx2.5⁺). Representative immunohistochemical images and pooled data [A–C; CTL (wild-type), vehicle and cardiosphere-derived cell-treated Gαq mouse hearts stained for Ki67 (A), aurora B (B), c-kit and Nkx2.5 (C)] from Gαq mice treated at 8 weeks of age. Arrows point to Ki67⁺ (A) and aurora B⁺ (B) cardiomyocytes and the cells positive for both c-kit and Nkx2.5 (C). Fractions of cycling (Ki67⁺) and proliferating (Aurora B⁺) cardiomyocytes are expressed as the number of Ki67⁺ and aurora B⁺ cardiomyocytes divided by the total number of cardiomyocytes per high-power field, respectively [pooled data (A) and (B)]. The portion of c-kit⁺Nkx2.5⁺ cells was calculated as the number of c-kit⁺Nkx2.5⁺ cells divided by the total number of cardiomyocytes per HPF [pooled data (C)]. Wheat germ agglutinin was applied for staining and delineation of cell membrane. Data are means ± SEM; n = 6–8 in each group. †P < 0.01 vs. Gαq+Vehicle and control (CTL; wild-type); scale bars: 10 μm.
Survival analysis, changes in antioxidant defence pathway, and schematic summary of key findings. (A) Kaplan–Meier approach was applied for assessment of survival rate ($n=8$ in each group). Survival was significantly attenuated in vehicle-treated G$q$ mice relative to either cardiosphere-derived cell-treated G$q$ mice or wild-type controls after adriamycin insult; the latter two groups, however, were statistically indistinguishable ($P<0.001$, log-rank test). Cardiosphere-derived cell treatment restored activity of antioxidant pathway, Nrf2-Keap1. Representative western blots and pooled data from G$q$ mice treated at 8 weeks of age demonstrate restored protein content of nuclear Nrf2, cytoplasmic Keap1 and the downstream gene products of Nrf2, catalase, and copper-zinc superoxide dismutase (Cu-Zn SOD), with cardiosphere-derived cell treatment. Membranes were stripped and GAPDH and histone H1 probed as a control for loading in each lane. Data are means $\pm$ SEM; $n=6–8$ in each group. $†P<0.005$ vs. G$q$+CDC and control (CTL; wild-type). (C) Various deleterious pathways are up-regulated in the G$q$ model of dilated cardiomyopathy. Treatment with cardiosphere-derived cell impacted favourably on key disease processes including oxidative stress, inflammatory and remodelling pathways, apoptosis, and fibrosis.
Stimulation of the Gqα signalling pathway also exerts downstream effects via the PKC–PKD–CREB axis.17 Activation of PKC and subsequent phosphorylation and nuclear translocation of PKD recruits CREB to target genes including those involved in adverse remodelling.28–30 Of note, the roles of PKC–PKD–CREB signalling in pathological cardiac remodelling extend to inactivation of the pro-survival kinase, Akt kinase, and activation of the pro-apoptotic mediator, JNK.18 In CDC-treated Gαq mice, CDC restored activity of PKC and its downstream effectors, PKD and CREB, prevented inactivation of Akt and activation of JNK, and blunted apoptosis.

Temporal considerations of cardiosphere-derived cell benefit

The beneficial effects of CDCs on cardiac global function persisted for at least 3 months. This model, however, is one of constitutive expression of Gqα; there is good reason to expect that the benefits of CDCs may be transient, as newly generated myocytes themselves succumb to oxidative stress. Consistent with this prediction, cardiac 3-nitrotyrosine levels in CDC-treated mice were higher 3 months after treatment than at 3 weeks, although they still remained lower than in vehicle-treated mice (Supplementary material online, Figure S8). This finding hints that the beneficial effects of CDCs may wear off over time; if so, periodic re-administration of CDCs may be necessary to maintain longer-term functional improvement. Nevertheless, physiological deterioration is halted for at least 3 months, and survival, as one of the main treatment goals in heart failure,39 is markedly enhanced when CDC-treated animals are challenged by a cardiotoxic insult. Why do the beneficial effects of CDCs last as long as they do? Among the various mechanisms, CDCs promote cardiomyocyte proliferation. The newly generated myocytes benefit from the antioxidant, anti-fibrotic, and anti-inflammatory milieu established, at least temporarily, by the CDCs; presumably it takes some time for these new myocytes to succumb to the progressive stress of Gαq overexpression, just as several weeks of postnatal life are required for cardiac dysfunction to become manifest in the first place.

Limitations

The present study has several important limitations. The mouse model of DCM, although well-studied and reproducible, may not be predictive for the human condition. The duration of observation post-treatment was limited to 3 months in the functional and tissue studies and to 4 months in the survival analysis; longer-term studies will be required to accurately define the time course of persistence of benefit, as well as the possible utility of repeat dosing. Here, we have used single dosing with wild-type mouse CDCs derived from the founder strain; we do not anticipate immunologic reactions in syngeneic therapy with highly inbred mice,1,25 but we recognize that such reactions will need to be carefully assessed before repeat dosing of allogenic products is contemplated in humans. Finally, the study was designed to determine whether CDCs are beneficial in the Gαq mouse model of DCM, and, if so, whether the core pathophysiological processes at play are influenced by CDCs. While we have addressed these questions, we have not attempted here to pinpoint the root mechanisms of benefit, other than to establish that the mechanisms must be indirect.

In summary, CDC treatment prevents functional deterioration, attenuates oxidative/nitrosative stress, promotes cardiomyocyte proliferation and reduces mortality in a transgenic mouse model of DCM.

Supplementary material

Supplementary material is available at European Heart Journal online.
Funding

This work was supported by the Lincy Foundation and the Cedars-Sinai Board of Governors Heart Stem Cell Center. General laboratory support is also derived from grants to E.M. from the NIH and the California Institute of Regenerative Medicine. K.C. was supported by the American Heart Association Beginning Grant-In-Aid and K.M. was supported by a research award from the International Society for Heart and Lung Transplantation.

Conflict of interest: E.M. is founder and equity holder in Capricor. Inc. K.M. receives consulting income from Capricor. The other authors report no conflicts.

References

17. Malliaras K, Marban E. Cardiac cell therapy: Where we’ve been, where we are, and where we should be headed. Br Med Bull 2011;98:161–185.
Single coronary artery anomaly with interarterial left main: caught inbetween

L. Christian Napp1*, Imke Schatka2, Tibor Kempf1, Udo Bavendiek1, Frank M. Bengel2, and Johann Bauersachs1

1Department of Cardiology and Angiology OE 6880, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany and 2Department of Nuclear Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Hannover, Germany

*Corresponding author. Tel: +49 176 1532 5735, Fax: +49 511 532 5412, Email: napp.christian@mh-hannover.de

An 82-year-old patient with suspected pulmonary hypertension was referred to our department for cardiac catheterization. Right heart catheterization confirmed precapillary pulmonary hypertension. Coronary angiography revealed that the left main (LMCA, arrowhead) originated from the right sinus of valsalva in a common ostium together with the RCA (circle) (Panels A and B, Supplementary material online, Videos S1 and S2). Computed tomography confirmed that the LMCA (arrow) passed between the aorta (AO) and the right ventricular (RV) outflow tract and gave rise to the LAD before running towards the lateral wall as LCX (Panels C and D). Computed tomography confirmed the absence of an additional coronary artery, thus the patient had a congenital single coronary artery anomaly with an interarterial left main.

Single coronary artery anomaly has an estimated prevalence of <0.1% in the general population. Various subtypes are classified depending on the origin and route of coronary arteries. Our patient had subtype RII-B according to the nomenclature published by Lipton et al. in 1979. In cases with an interarterial course, the coronary artery is prone to be compressed between the great arteries. Such patients are at increased risk for myocardial infarction and sudden death even in the absence of atherosclerosis, e.g. during exercise or other situations great artery enlargement such as pulmonary hypertension. Surgical revascularization may be indicated for prevention of sudden death according to current guidelines. In our case, due to the age of the patient we recommended a conservative strategy and advised to avoid intensive physical exercise. Once coronary artery anomalies are found, computed tomography should be performed to unequivocally determine anatomical relations.

Supplementary Material is available at European Heart Journal online.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com.